Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UNG is a good one for this winter. I am with you on this one
UNG
VGPR chart
I am back in whole hog. I love these biotech and medical device plays. They are risky--but clinical data can really move them.
fastlizz--check out this medical device company with FDA approval
CTT looks like it could just be starting, IMO.
CTT
CTT on watch
LOL, allwaysright--why were you in IHUB jail?
I thought he was in jail-- literally.
Have you talked to BLVT about getting someone who knows how to write PR's? This company has, what appears, to be great revenues and yet the stock is headed down. Based on their PR's--I would not feel comfortable in buying more. They need to highlight in the headings how big the Revenues are and the size of the Army contract.
Instead, they have these pathetic shareholder update PR's which DO NOT ATTRACT new investors. And that is why BLVT is down here.
WHy buy more of a stock that you are stuck in? And why would a new potential investor buy here when the "good news" on contracts is not resulting in more volume and more buying?
It kind of makes you feel that there is more to the story--and it ain;t positive.
All fixable--but they really do not seem to know how to communicate their story.
IWEB has been great and looks like it is not just a short term deal. Hope you are in some.
Thanks, MR. Bigz. IWEB has been a horse that pauses and consolidates. ANd the news they have been putting out is not like the typical micro-cap.
Cheers
Are you still in IWEB, WANG?
IWEB is a monster and holding in after a 140% move
Now, you have to admit that the IWEB chart looks really good with a higher base.
Matt--IWEB on the move again
Watch CTT today on this news, icon. Real company with revenues--finally
Competitive Technologies Booking Revenue From Worldwide Shipments of Pain Therapy Medical Devices
FAIRFIELD, Conn., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that it is moving forward with its plan to restore profitability. Its Calmare Therapy Treatment*, pain therapy medical device is treating patients in several locations worldwide. Revenue for product shipments has been recorded for shipments made during the fiscal quarter ended October 31, 2009.
The first shipment of 10 devices has been received by CTT's Switzerland-based distributor, Life Episteme Group. This shipment will be followed by four additional shipments of 10 devices each. In the U.S., Calmar Pain Relief, LLC, of North Providence, RI, has received two devices at its offices in Rhode Island in anticipation of the official opening of its pain therapy clinic on November 16, 2009. Four additional devices have been shipped to other organizations in the U.S. and one device has also been shipped to Biogene Pharma, Ltd., CTT's distributor in Bangladesh.
"Revenue is recorded based on shipments rather than orders from these devices and has been booked in the first quarter of fiscal year 2010," according to John B. Nano, CTT's Chairman, President and CEO. "We expect to see revenues from sales of our Calmare Therapy Treatment grow throughout the fiscal year.
"Each of CTT's five directors has recently made an open market purchase of CTT stock, which demonstrates confidence in CTT's performance. These stock purchases and the above actions followed the 'going concern' statement describing our financial condition that was included in our Form 10-K and auditors report, filed October 27, 2009. Our plans to improve profitability were also included in our Form 10-K, along with a summary of our $8 million equity financing agreement with Fusion Capital Fund II, LLC."
CTT has exclusive worldwide rights to the Calmare Therapy Treatment device, which was developed in Italy by CTT's client, Prof. Giuseppe Marineo. The Calmare Therapy Treatment has been used to treat more than 3,000 patients in Europe and the US. CTT partner, GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution. For more information about the device, visit www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
* The Calmare Therapy Treatment uses Competitive Technologies' MC-5A pain therapy medical device to provide rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other narcotic painkillers.
Contact:
IR Services, LLC
Johnnie D. Johnson,
860 434 2465
jdjohnson@corpirservices.com
CTT news out today with sales numbers
Competitive Technologies Booking Revenue From Worldwide Shipments of Pain Therapy Medical Devices
FAIRFIELD, Conn., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that it is moving forward with its plan to restore profitability. Its Calmare Therapy Treatment*, pain therapy medical device is treating patients in several locations worldwide. Revenue for product shipments has been recorded for shipments made during the fiscal quarter ended October 31, 2009.
The first shipment of 10 devices has been received by CTT's Switzerland-based distributor, Life Episteme Group. This shipment will be followed by four additional shipments of 10 devices each. In the U.S., Calmar Pain Relief, LLC, of North Providence, RI, has received two devices at its offices in Rhode Island in anticipation of the official opening of its pain therapy clinic on November 16, 2009. Four additional devices have been shipped to other organizations in the U.S. and one device has also been shipped to Biogene Pharma, Ltd., CTT's distributor in Bangladesh.
"Revenue is recorded based on shipments rather than orders from these devices and has been booked in the first quarter of fiscal year 2010," according to John B. Nano, CTT's Chairman, President and CEO. "We expect to see revenues from sales of our Calmare Therapy Treatment grow throughout the fiscal year.
"Each of CTT's five directors has recently made an open market purchase of CTT stock, which demonstrates confidence in CTT's performance. These stock purchases and the above actions followed the 'going concern' statement describing our financial condition that was included in our Form 10-K and auditors report, filed October 27, 2009. Our plans to improve profitability were also included in our Form 10-K, along with a summary of our $8 million equity financing agreement with Fusion Capital Fund II, LLC."
CTT has exclusive worldwide rights to the Calmare Therapy Treatment device, which was developed in Italy by CTT's client, Prof. Giuseppe Marineo. The Calmare Therapy Treatment has been used to treat more than 3,000 patients in Europe and the US. CTT partner, GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution. For more information about the device, visit www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
* The Calmare Therapy Treatment uses Competitive Technologies' MC-5A pain therapy medical device to provide rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other narcotic painkillers.
Contact:
IR Services, LLC
Johnnie D. Johnson,
860 434 2465
jdjohnson@corpirservices.com
CTT news out today with sales numbers
Competitive Technologies Booking Revenue From Worldwide Shipments of Pain Therapy Medical Devices
FAIRFIELD, Conn., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that it is moving forward with its plan to restore profitability. Its Calmare Therapy Treatment*, pain therapy medical device is treating patients in several locations worldwide. Revenue for product shipments has been recorded for shipments made during the fiscal quarter ended October 31, 2009.
The first shipment of 10 devices has been received by CTT's Switzerland-based distributor, Life Episteme Group. This shipment will be followed by four additional shipments of 10 devices each. In the U.S., Calmar Pain Relief, LLC, of North Providence, RI, has received two devices at its offices in Rhode Island in anticipation of the official opening of its pain therapy clinic on November 16, 2009. Four additional devices have been shipped to other organizations in the U.S. and one device has also been shipped to Biogene Pharma, Ltd., CTT's distributor in Bangladesh.
"Revenue is recorded based on shipments rather than orders from these devices and has been booked in the first quarter of fiscal year 2010," according to John B. Nano, CTT's Chairman, President and CEO. "We expect to see revenues from sales of our Calmare Therapy Treatment grow throughout the fiscal year.
"Each of CTT's five directors has recently made an open market purchase of CTT stock, which demonstrates confidence in CTT's performance. These stock purchases and the above actions followed the 'going concern' statement describing our financial condition that was included in our Form 10-K and auditors report, filed October 27, 2009. Our plans to improve profitability were also included in our Form 10-K, along with a summary of our $8 million equity financing agreement with Fusion Capital Fund II, LLC."
CTT has exclusive worldwide rights to the Calmare Therapy Treatment device, which was developed in Italy by CTT's client, Prof. Giuseppe Marineo. The Calmare Therapy Treatment has been used to treat more than 3,000 patients in Europe and the US. CTT partner, GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution. For more information about the device, visit www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
* The Calmare Therapy Treatment uses Competitive Technologies' MC-5A pain therapy medical device to provide rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other narcotic painkillers.
Contact:
IR Services, LLC
Johnnie D. Johnson,
860 434 2465
jdjohnson@corpirservices.com
HEMP is in. Pills are out. LOL
CTT on the move today on good news, matthew
Competitive Technologies (CTT) Booking Revenue From Worldwide Shipments of Pain Therapy Medical Devices
FAIRFIELD, Conn., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that it is moving forward with its plan to restore profitability. Its Calmare Therapy Treatment*, pain therapy medical device is treating patients in several locations worldwide. Revenue for product shipments has been recorded for shipments made during the fiscal quarter ended October 31, 2009.
The first shipment of 10 devices has been received by CTT's Switzerland-based distributor, Life Episteme Group. This shipment will be followed by four additional shipments of 10 devices each. In the U.S., Calmar Pain Relief, LLC, of North Providence, RI, has received two devices at its offices in Rhode Island in anticipation of the official opening of its pain therapy clinic on November 16, 2009. Four additional devices have been shipped to other organizations in the U.S. and one device has also been shipped to Biogene Pharma, Ltd., CTT's distributor in Bangladesh.
"Revenue is recorded based on shipments rather than orders from these devices and has been booked in the first quarter of fiscal year 2010," according to John B. Nano, CTT's Chairman, President and CEO. "We expect to see revenues from sales of our Calmare Therapy Treatment grow throughout the fiscal year.
"Each of CTT's five directors has recently made an open market purchase of CTT stock, which demonstrates confidence in CTT's performance.
Good Morning, BB. Ready for a GREEN day?
HESG should run on news today on Obama's Medical Pot Policy
Good luck?
Thanks, but I have not owned CYBL for a year or so and made money on a run. I am just saying that CYBL's ONLY chance is to get rolled into a company with revenue--take the hit on dilution--stock goes down alot more--but THEN buy in depending upon the business plan of the revenue company.
Other than that--you are right--this goose is cooked.
LOL.
GL
Who is "fed Ben"?
More news coming this week--mgmt upset with selloff for no real reason.
Thanks,allwaysright, for the info. Investors obviously do not believe the numbers in their PR's, otherwise,BLVT would be much higher.
And the "good" news sure is not presented well. Most companies would trumpet that the previously annnounced Army contract of $39 Million is really even higher! Ant talk about unexcitinng headings--"BLVT Announces Shareholder Update"
YAWN!--but buried in the text is the revelation of a 7% bigger number for the contract.
Do you know any of those guys at BLVT, allwaysright? Do us all a favor and give them some of this feedback.
We cannot wait until the audited numbers come out in Dec to find out that the PR's are reals.
Cheers and GLTA
News out on Monday.
NXT Nutritionals' SUSTA, the Great Tasting All-Natural Sweetener, Is Being Featured on "The Balancing Act" TV Series -- Airing This Fall on the Lifetime Channel
* Press Release
* Source: NXT Nutritionals Holdings, Inc.
* On 9:01 am EST, Monday November 2, 2009
o
Buzz up! 0
o Print
*
Companies:
o Nxt Nutritionals Holdings, Inc.
HOLYOKE, Mass.--(BUSINESS WIRE)--NXT Nutritionals Holdings, Inc. (“NXT Nutritionals”) (OTCBB: NXTH - News) developer and marketer of SUSTA™ Natural Sweetener, the great tasting, all-natural, healthier sweetener, announced today that NXT Nutritionals spokesperson Blair Underwood will discuss the health benefits and good taste of SUSTA on “The Balancing Act”, a daily morning half-hour talk show for women on the Lifetime channel.
Related Quotes
Symbol Price Change
NXTH.OB 2.19 +0.18
Chart for NXT NUTRITIONALS HLD
{"s" : "nxth.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Blair Underwood and SUSTA™ Natural Sweetener will be featured throughout the holiday season on the talk show in a six to eight minute segment called “Home For The Holidays: Healthy Alternatives to Sweeten the Holiday”, starting November 27.
“The Balancing Act” on the Lifetime channel potentially reaches over 96 million households and is a show for women who want a fast-paced half-hour of news and information including advice from the country’s leading experts as well as covering great topics like -- health, family, finances and lifestyle. "The Balancing Act" airs on Lifetime Television, Monday – Friday at 7:30 a.m. (EST/PST)
Michael McCarthy, president and CEO of NXT Nutritionals, said, “Blair Underwood’s appearances on “The Balancing Act” are a great opportunity to present our amazing, healthy all-natural sweetener SUSTA to television viewers. “The Balancing Act” is an excellent showcase for the health benefits that SUSTA provides because we believe that its audience makes healthy living a priority in their lives.”
SUSTA is targeted at individuals for whom sugar is either not a viable option, or is an undesirable option, such as diabetics, individuals on weight loss programs, and those proactively managing obesity. SUSTA is the only sweetening system in the retail marketplace that is all-natural, low glycemic, contains soluble fiber and probiotics, vitamins C, B6 and B12 and essential minerals and that helps to maintain healthy blood sugar levels, aids digestion as well as supports the immune system.
About The Balancing Act
“The Balancing Act” on the Lifetime channel potentially reaches over 96 million households and is America’s premier morning TV talk show about women, for women, and trusted by women. “The Balancing Act” is a show for women who want a fast-paced half-hour of news you can use, and endless entertainment! This includes your daily dose of trends and tips featuring advice from the country’s leading experts as well as covering great topics like -- health, family, finances and lifestyle. Bringing a great balance to the show are hosts Beth Troutman, and Kristy Villa. They bring not only their tastes — but a whole new flavor to “The Balancing Act”. “The Balancing Act” airs on Lifetime Television, Monday – Friday at 7:30 a.m. (EST/PST) For more information, go to www.thebalancingact.com.
About NXT Nutritionals Holdings, Inc.
Headquartered in Holyoke, MA, NXT Nutritionals Holdings, Inc., through its wholly owned subsidiary NXT Nutritionals, Inc., is a developer and marketer of proprietary, patent-pending healthy alternative sweeteners, food and beverage products. The common ingredient for all of the Company’s products is its SUSTA™ Natural Sweetener, a minimal calorie, all-natural, nutritional sweetening system. SUSTA™ Natural Sweetener currently serves as an ingredient for the Company’s nonfat all-natural Healthy Dairy™ yogurt smoothies and is marketed as a standalone product as well.
For comprehensive investor relations material, including fact sheets, research reports, interviews and video, please follow the appropriate link: Investor Relations Portal, Board of Directors Interview and Overview Video.
For additional information, please visit NXT Nutritionals’ corporate website: www.nxtnutritionals.com.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of NXT Nutritionals Holdings, Inc. can be found in the filings of NXT Nutritionals Holdings, Inc. with the U.S. Securities and Exchange Commission.
Contact:
Company Contact:
NXT Nutritionals Holdings, Inc.
Michael McCarthy, President and CEO
1-800-535-4315
moreinfo@nxtnutritionals.com
or
Public Relations/Media Contact:
Richard Stern
Stern & Co.
212-888-0044
richstern@sternco.com
or
Financial Communications Contact:
Trilogy Capital Partners
Darren Minton, Vice President
Toll-free: 800-592-6067
info@trilogy-capital.com
VCTY was at .0014
Bottom line is that CYBL has to find a way to bring in revenue to the point where they can STOP the dilution--even if it means allowing a private company to reverse merge into it. That will be more dilution --but it at least means that there is a chance for the dilution to stop or slow down.
JMO
Who is Redwood?
It would help if they had better PR writers. What they have to say is impressive, HOW they said is horrible, imo.
vspc
hrnf
VCTY CHART
VCTY CHART
VVUS to Gap higher tomorrow
Disgusting chart
BLVT on Bounce Watch
bobby? Did you get any NXTH?
I am expecting a PR from management on Monday.
It took a quick decision when it was scary, but buying in at $1.41 has been my best two day trade this year (so far).
Now, I hope I did not just jinx myself.
Money flow looks horrible on ESLR now.
Watching for a flush and a bounce play
CHART on CIT
Bottom play--BEAT--and--cha ching--NXTH
BEAT
BEAT hit my scan today. Here we go!